Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer

@article{Mahler1998ClinicalPO,
  title={Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer},
  author={Ch. Mahler and Johan A. Verhelst and Louis J. Denis},
  journal={Clinical Pharmacokinetics},
  year={1998},
  volume={34},
  pages={405-417}
}
Prostatic cancer is the second most common cause of cancer death in males. Treatment by radical prostatectomy and radiotherapy is useful in the early stages of the disease. Whenever metastases occur, patients are usually treated by surgical (orchidectomy) or medical [gonadotropin releasing hormone (GnRH) analogue] castration. This form of treatment is, however, associated with unwanted adverse effects, such as flushing, loss of libido and potency and all patients ultimately escape therapy after… Expand
The role of antiandrogen monotherapy in the treatment of prostate cancer
TLDR
Current data are inadequate to draw conclusions on the comparative efficacy of flutamide and castration, while nilutamide is not licensed for monotherapy, and bicalutamide has a more favourable side‐effect profile than the other antiandrogens and is more likely to promote compliance. Expand
Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer.
TLDR
New-generation hormonal therapies being increasingly used in all stages of disease, more patients may experience the withdrawal syndrome when stopping the treatment at the time of disease progression, although the clinical relevance of this phenomenon in the management of metastatic castration-resistant prostate cancer remains to be defined. Expand
Non-steroidal anti-androgens in prostate cancer - current treatment practice
TLDR
The benefits of NSAA in monotherapy, intermittent or neoadjuvant therapy are not clear at present, and better designed, larger cohort clinical trial may be necessary to clarify the confusion. Expand
Antiandrogen monotherapy: indications and results.
TLDR
Bicalutamide 150-mg monotherapy was associated with significant advantages compared with castration, in terms of sexual interest and physical capacity, in patients with either M0 and M1 stage disease, and emerging evidence also supports the use of bicalUTamide 150 mg, both as immediate monotherapy and as adjuvant therapy in early stage (localized or locally advanced) prostate cancer. Expand
An evaluation of bicalutamide in the treatment of prostate cancer
TLDR
Mature survival data from men with previously untreated, locally-advanced prostate cancer reveal that bicalutamide monotherapy provides survival benefits that do not differ significantly from castration, while offering important advantages with respect to the maintenance of physical capacity and sexual interest. Expand
Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics
TLDR
Second-line agents, traditionally reserved for CRPC, are being studied in metastatic castrate-sensitive prostate cancer, and may offer practice-changing evidence supporting their use. Expand
Androgen Deprivation Therapy for Prostate Cancer.
  • V. Pagliarulo
  • Medicine, Biology
  • Advances in experimental medicine and biology
  • 2018
TLDR
Different hormonal compounds available for the treatment of PC are compared, both from a pharmacological standpoint, and in terms of contemporary clinical indications. Expand
Retrospective Analysis of Clinical Efficacy of Luteinizing Hormone-Releasing Hormone Antagonist as Compared to Agonists with Combined AntiAndrogen Blockade ( CAB ) in Advanced Prostate Cancer
Purpose: we retrospectively analyzed the clinical efficacy of the LHRH antagonist degarelix and compared it with that of the LHRH agonist's leuprolide or goserelin when used in combination with aExpand
Bicalutamide (Casodex®) in the treatment of prostate cancer
  • Y. Fradet
  • Medicine
  • Expert review of anticancer therapy
  • 2004
TLDR
Nonsteroidal antiandrogens such as bicalutamide (Casodex®) offer an effective alternative to castration with potential quality-of-life benefits in men with prostate cancer. Expand
Recent developments in antiandrogens and selective androgen receptor modulators
TLDR
Progress still needs to be made in order to find compounds with an improved profile with regard to efficacy, differentiation and side-effects, and this will only be achieved through a better understanding of the mechanisms involved in normal and aberrant AR signaling. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 58 REFERENCES
Defining the role of antiandrogens in the treatment of prostate cancer.
TLDR
Protocols have been developed to assess the clinical potential of bicalutamide as the sole adjuvant therapy in these postprostatectomy patients, based in no small part on the relative paucity of side effects of this antiandrogen. Expand
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
TLDR
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade. Expand
New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens
TLDR
The present data show that complete withdrawal of androgens by combined hormonal therapy with the LHRH agonist (or castration) and a pure antiandrogen leads to a positive objective response in more than 95% of cases as opposed to 60%‐70% as reported by many groups using the previous partial hormonal therapy. Expand
Withdrawal phenomenon with the antiandrogen casodex.
  • P. Nieh
  • Medicine
  • The Journal of urology
  • 1995
TLDR
The observations in this report would suggest that the initial and sustained exposure to an antiandrogen is the more important factor in the withdrawal phenomenon rather than the low androgen environment alone that occurs with initial luteinizing hormone-releasing hormone analogue monotherapy, orchiectomy or combination lute inizing hormones-re releasing hormone analogue and anti androgen. Expand
Cyproterone acetate–‐mechanism of action and clinical effectiveness in prostate cancer treatment
TLDR
The usefulness of CPA in the management of prostate cancer, especially in total androgen blockade regimens, recently has been challenged by findings in experimental systems that suggest that CPA is androgenic. Expand
Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
TLDR
The results indicate that nilutamide as a single agent has an acceptable toxicity and a moderate activity, and may maintain sexual interest in a discrete number of cases, and whether monotherapy with nonsteroidal antiandrogens offers a valid option in the palliation of advanced disease remains to be seen in comparative prospective trials. Expand
Ocular toxicity of Anandron in patients treated for prostatic cancer.
TLDR
The availability of a compound such as flutamide that has no side effect other than those due to hypoandrogenicity should greatly facilitate compliance by the patients and the success of the treatment of prostatic cancer. Expand
A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.
TLDR
A comparison of pharmacologic effects showed that only the incidence of hot flushes was lower in the bicalutamide group, whereas breast tenderness and gynecomastia were more common, which translated into better quality of life during the first several months with regard to sexual relations and sexual functioning. Expand
Indications for Antiandrogen Treatment in Prostate Cancer
The modern concept of antiandrogenic activity in prostate cancer has its origin in the development of cyproterone acetate (CPA) in 1962. Antiandrogens were first defined by Dorfman as substances thatExpand
Combination Therapy with Flutamide: The Therapy of Choice from Early to Advanced Stages of Prostate Cancer
TLDR
A high rate of positive responses is already quite impressive since, as will be discussed later, testicular androgens account for only 60% of total androgens in 65-year-old men, thus leaving approximately 40% of androgens free to continue to stimulate prostate cancer. Expand
...
1
2
3
4
5
...